World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
44826
World Ranking
8803
National Ranking
101

Marc Peeters publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Marc Peeters sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 830 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Marc Peeters D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Marc Peeters sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Marc Peeters is affiliated with the University of Antwerp in Belgium and has an extensive publication record specializing in oncology and related medical fields. Their research contributions are primarily focused on cancer treatments, immunotherapy, genomics, and diagnostics, among other medical subfields. Peeters has contributed to over 400 publications in medicine, with a significant emphasis on oncology.

Their recent published papers include:

  • Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study (2023, The Lancet Oncology)
  • Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review (2022, Journal of Bone Oncology)
  • Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial (2020, Annals of Oncology)
  • Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment (2021, ESMO Open)
  • Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer (2021, Redox Biology)

Marc Peeters has collaborated extensively with other researchers. Frequent co-authors include:

  • Peter A. van Dam
  • Timon Vandamme
  • Hans Prenen
  • Evelien Smits
  • Filip Lardon

Their scholarly work has been published in various prominent journals, with multiple contributions to:

  • Annals of Oncology
  • Cancers
  • ESMO Open
  • European Journal of Cancer
  • Journal of Clinical Oncology

Marc Peeters has written on several main topics within their field including:

  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Gastric Cancer Management and Outcomes
  • Cancer Genomics and Diagnostics
  • COVID-19 and Healthcare Impacts
  • Pancreatic and Hepatic Oncology Research
  • Lung Cancer Treatments and Mutations

Their publications span subfields such as:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Cancer Research
  • Surgery

Marc Peeters is also an author of a textbook published by Springer International Publishing titled Practical Medical Oncology Textbook (2021), which has been cited in academic literature.

Best Publications

  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

    Rafael G. Amado;Michael Wolf;Marc Peeters;Eric Van Cutsem

  • Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

    Eric Van Cutsem;Marc Peeters;Salvatore Siena;Yves Humblet

  • Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    Robert J Mayer;Eric Van Cutsem;Alfredo Falcone;Takayuki Yoshino

  • Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

    Marianne E Pavel;John D Hainsworth;Eric Baudin;Marc Peeters

  • Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

    Marc Peeters;Timothy Jay Price;Andrés Cervantes;Alberto F. Sobrero

  • KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

    W. De Roock;H. Piessevaux;J. De Schutter;M. Janssens

  • Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum

    P Rutgeerts;M Peeters;M Hiele;G Vantrappen

  • Controlled trial of metronidazole treatment for prevention of crohn's recurrence after ileal resection☆

    Paul Rutgeerts;Martin Hiele;Karel Geboes;Marc Peeters

  • Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

    D. Arnold;B. Lueza;J.-Y. Douillard;M. Peeters

  • Utility of Positron Emission Tomography for the Staging of Patients With Potentially Operable Esophageal Carcinoma

    P Flamen;A Lerut;E Van Cutsem;W De Wever

  • Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis

    Filip J. Baert;Geert R. D'Haens;Marc Peeters;Martin I. Hiele

  • Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

    E. Van Cutsem;F. Rivera;S. Berry;A. Kretzschmar

  • Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

    Timothy J Price;Marc Peeters;Tae Won Kim;Jin Li

  • Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis.

    G D'Haens;L Lemmens;Karel Geboes;L Vandeputte

  • Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.

    Alain Hendlisz;Marc Van Den Eynde;Marc Peeters;Geert Maleux

  • Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease

    Marc Peeters;Sofie Joossens;Severine Vermeire;Robert Vlietinck

  • Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

    Bart Jacobs;Wendy De Roock;Hubert Piessevaux;Robin Van Oirbeek

  • Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics

    M Peeters;H Nevens;F Baert;M Hiele

  • The value of serologic markers in indeterminate colitis : a prospective follow-up study

    Sofie Joossens;Walter Reinisch;Séverine Vermeire;Boualem Sendid

  • A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

    Helmut Oettle;D. Richards;R. K. Ramanathan;J. L. van Laethem

Frequent Co-Authors

Patrick Pauwels
Patrick Pauwels University of Antwerp
Jan B. Vermorken
Jan B. Vermorken University of Antwerp
Salvatore Siena
Salvatore Siena University of Milan
Evelien Smits
Evelien Smits University of Antwerp
Guy Van Camp
Guy Van Camp University of Antwerp
Antonio Russo
Antonio Russo University of Palermo
Volker Heinemann
Volker Heinemann Ludwig-Maximilians-Universität München

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine but aren’t ready for the commitment of a traditional MD program, there are several related pathways to explore. Many students begin by looking into nursing schools, and you might wonder what is the easiest nursing school to get into to jumpstart your healthcare journey.

For those interested in a non-clinical role, medical billing and coding schools online offer flexible programs that can prepare you for administrative and IT-focused positions in the healthcare industry.

There are also fast-track options for current nurses, such as lpn to rn programs without teas test, which eliminate common admission exams and help you advance your credentials quickly.

If you’re drawn to leadership and organizational roles, a healthcare administration online degree can open doors to managerial positions in hospitals, clinics, and more—all from the convenience of your home.

Best Scientists Citing Marc Peeters

Trending Scientists

Recently Published Articles